ResMed Inc. stock gains on RBC upgrade and fresh FY27 guidance
Published on 09/16/2026 at 17:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. stock (ISIN US7611521078) has climbed after a fresh upgrade from RBC Capital Markets and new guidance for fiscal 2027 signaled mid-single-digit revenue growth and double-digit earnings expansion as of September 15, 2026. According to Investing.com on September 15, 2026, management now projects currency-adjusted core revenue to grow 5% to 7% and core EPS to increase 12% to 14% in fiscal 2027.
RBC upgrade and FY27 outlook support ResMed Inc. stock
As MarketBeat reported on September 15, 2026, Royal Bank of Canada raised its rating on ResMed from Sector Perform to Outperform and lifted its price objective from USD 244.00 to USD 262.00, implying a higher expected upside for the shares.
According to GuruFocus on September 15, 2026, the upgrade came after ResMed delivered strong fourth-quarter earnings, and the new price target of USD 262 compares with a trading price around USD 233.06, which GuruFocus described as roughly 12.9% below its calculated GF Value of USD 267.59.
In parallel, management used the Morgan Stanley Global Healthcare Conference to outline its first formal guidance for fiscal 2027. As Investing.com noted on September 15, 2026, ResMed now expects currency-adjusted core revenue growth of 5% to 7% and core EPS growth of 12% to 14% in the upcoming fiscal year, positioning the company for earnings expansion that outpaces sales.
Q4 fiscal 2026 results show solid revenue and EPS growth
The positive rating change and guidance build on recently reported fourth-quarter fiscal 2026 figures. According to MarketBeat, ResMed reported quarterly EPS of USD 2.95 in Q4 of fiscal 2026, beating market estimates, while revenue increased 8.6% year over year to USD 1.46 billion.
As Simply Wall St wrote on September 16, 2026, ResMed delivered 8.6% year-on-year revenue growth to USD 1.46 billion in Q4 2026, alongside non-GAAP diluted EPS growth of 16% to USD 2.95, showing that earnings increased significantly faster than sales.
The same analysis from Simply Wall St highlighted that this earnings beat came despite operating margin pressure linked to higher research and development spending and supply chain costs, which had previously weighed on investor sentiment when the results were first released in early August 2026.
Capital returns, dividend increase and buyback plan
Beyond the near-term earnings beat, ResMed has stepped up capital returns to shareholders. According to MarketBeat, the company raised its quarterly dividend from USD 0.60 per share to USD 0.66 per share, an increase of 10%, with the higher payout to be distributed to shareholders of record on August 20, 2026.
As Barchart reported on September 15, 2026, ResMed also announced a USD 1.5 billion buyback program for fiscal 2027, signaling its commitment to enhancing shareholder returns over the coming year.
Another element of the capital return strategy is the accelerated share repurchase program. According to Moomoo on September 16, 2026, a September SEC filing disclosed a USD 450 million accelerated share repurchase agreement funded by proceeds from the MatrixCare sale and cash on hand, contributing to management's plan to return more than USD 1.85 billion to shareholders during fiscal 2027 through buybacks and dividends.
Operational trends and competitive backdrop
The RBC upgrade also reflects ResMed's operating trends in its core sleep devices segment. As Tikr noted on September 16, 2026, ResMed's Americas Sleep devices revenue grew 8% year over year in Q4 fiscal 2026, surpassing the mid-single-digit industry growth that RBC analyst Craig Wong-Pan had previously expected.
According to the same Tikr article, the upgrade arrived shortly after the US Food and Drug Administration issued a Class 1 recall, its most serious category, for React Health's Luna G3 sleep therapy device, a competing product in the obstructive sleep apnea market.
This recall adds to an industry backdrop already shaped by prior challenges at competitors, and RBC's view is that ResMed's strong market position in sleep apnea devices and accessories is an important asset as demand shifts and regulatory scrutiny remain high, supporting the more constructive rating and higher price target.
ResMed Inc. stock price context and trading metrics
Price data from the recent upgrade session show how the market responded. According to MarketBeat, during trading on September 15, 2026, ResMed shares on the New York Stock Exchange traded up 4.5%, reaching an intraday high of USD 233.23 and last trading around USD 232.99, with approximately 419,842 shares changing hands, which was 68% below the average session volume of 1,305,453 shares.
The same MarketBeat update pointed out that ResMed's fifty day simple moving average stood at USD 217.48 and its 200-day simple moving average at USD 216.49, indicating that the stock price around USD 233 was trading noticeably above both medium and longer-term trend lines in mid-September 2026.
In addition, Tikr noted that ResMed stock was down 16% over the last year as of September 15, 2026, with a share price of USD 229 compared with a 52-week high of USD 285, underscoring that the recent rally still leaves the shares below their peak despite the upgrade-driven move higher.
Risks investors are watching in ResMed Inc. stock
While the combination of an earnings beat, increased capital returns and an analyst upgrade supports ResMed Inc. stock, investors continue to monitor margin dynamics and broader sector risks. As Simply Wall St explained on September 16, 2026, ResMed's Q4 2026 revenue performance, while positive, was weaker relative to some peers, and higher spending on product development and logistics weighed on operating margins.
The same analysis from Simply Wall St noted that the stock fell around 2.3% immediately after the earnings release and was down about 5.1% on August 7, 2026, as the market digested the margin pressure, showing that profitability trends remain an important sensitivity for the share price.
ResMed Inc. stock closing level and investor takeaway
Per the price snapshot described by MarketBeat, ResMed Inc. stock recently traded around USD 232.99 on the New York Stock Exchange on September 15, 2026, placing the shares above their key moving averages but still below the 52-week high of USD 285 cited by Tikr.
ResMed Inc. stock facts
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Trading venue: NYSE
- Price (as of September 15, 2026): 232.99 USD
- Market capitalization: [value] USD (as of September 15, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
